An investor in NASDAQ:AKTX shares filed a lawsuit over alleged violations of Federal Securities Laws by Akari Therapeutics PLC.
Investors who purchased shares of Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
According to the complaint the plaintiff alleges on behalf of purchasers of Akari Therapeutics PLC (ADR) (NASDAQ:AKTX) common shares between March 30, 2017, and May 11, 2017, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between March 30, 2017, and May 11, 2017 the defendants failed to disclose that the Company’s CEO, and possibly other executives, were involved in publishing false information about the Company, including false information about the Phase 2 PNH trial of Coversin, that the Company lacked adequate checks and protections to prevent such behavior, and that, as a result of the foregoing, Defendants’ statements about Akari’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
Those who purchased NASDAQ:AKTX shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego